A clinical trial on the efficacy of IMOD in AIDS patients

Daru

Volumn 17, Issue 4, 2009, Pages 277-284

  Mohraz, M ^a   Khairandish, P ^a   Kazerooni, P A ^b   Davarpanah, M A ^b   Shahhosseiny, M H ^c   Mahdavian, B ^d   Vaziry, S ^d   Shahriary, S ^a   Kamali, K ^e   Khorram Khorshid, H R ^f,g   Heshmat, R ^d   Farhadi, M ^h   Gharibdoust, F ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^g AVICENNA RESEARCH INSTITUTE   (Iran)

^h IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

HIV AIDS; IMOD ; Phase II; Randomized clinical trial; Setarud

Indexed keywords

HERBACEOUS AGENT; IMOD; LAMIVUDINE; NELFINAVIR; SETARUD; UNCLASSIFIED DRUG; ZIDOVUDINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; IRAN; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 74549198840     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. UNAIDS.AIDS epidemic update. 2008
2. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, Hirschel B, Vernazza P, Francioli P, Greub G, Flepp M, Telenti A. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358(9290): 1322-1327.
3. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT. Antiretroviral Therapy-Associated Toxicities in the Resource-Poor World: the Challenge of a Limited Formulary. J Infect Dis. 2007; 196 Suppl 3; S449-456
4. Cerqueira DM, Amorim RM, Silva RR, Camara GN, Brigido MM, Martins CR. Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil. Mem Inst Oswaldo Cruz. 2004 Dec; 99(8): 877-882
5. Schwartlander B, Stover J, Walker N, Bollinger L, Gutierrez JP, McGreevey W, Opuni M, Forsythe S, Kumaranayake L, Watts C, Bertozzi S. Resource Needs for HIV/AKDS. Science 2001; 292: 2434-2436
6. Individual Members of the Faculty of Harvard University Consensus Statement on Antiretroviral Treatment for AIDS in Poor Countries. Cambridge: Harvard University, 2001. Accessed August 1, 2001. http://aids.harvard.edu/
7. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133(1): 21-30.
8. Herrmann S, McKinnon E, John M, Hyland N, Martinez OP, Cain A, Turner K, Coombs A. Evidencebased, multifactorial approach to addressing non-adherence to antiretroviral therapy and improving standards of care. J Antimicrob Chemother. 2005; 55(4): 413-416
9. Imami N, Hardy G, Gotch F. Development of immunotherapeutics strategies for HIV-1. Expert Opin Biol Ther 2001; 1(5): 803-816
10. Imami N, Westrop S, Cranage A, Burton C, Gotch F. Combined use of cytokines, hormones and therapeutic vaccines during effective antiretroviral therapy. Future HIV therapy 2007; 1: 171-179.
11. Conrad A. Interleukin-2--where are we going? J Assoc Nurses AIDS Care. 2003 Nov-Dec; 14(6): 83-88.
12. Farel CE, Chaitt DG, Hahn BK, Tavel JA, Kovacs JA, Polis MA, Masur H, Follmann DA, Lane HC, Davey RT Jr. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood. 2004; 103: 3282-3286.
13. Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, Michon C, Goujard C, Rouzioux C, Maral J, Delfraissy. JF, Emilie D, Aboulker JP. ANRS 079 Study Group. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003; 17: 343-351.
14. Henry K, Katzenstein D, Cherng DW, Valdez H, Powderly W, Vargas MB, Jahed NC, Jacobson J M, Myers LS, Schmitz JL, Winters M, Tebas P. A pilot study evaluating time to CD4 T-cell count <350 cells/ mm3 after treatment interruption following antiretroviral therapy ± interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr 2006; 42: 140-148.
15. Mark P, Agatha O, Nesrina I, Gareth H, Frances G, Neil A. Specificity of anti-human leukocyte antigen antibody responses after immunization with Remune, an inactivated HIV-1 vaccine. AIDS 2007; 21: 375-377.
16. Fernández-Cruz E, Navarro J, Gil J, Moreno S, González- Lahoz J, et al. The potential role of the HIV-1 immunogen (Remune® ) as a therapeutic vaccine in the treatment of HIV infection. Expert Rev Vaccines 2003; 2: 739-752.
17. Pett SL, Williams LA, Day RO, Lloyd AR, Carr AD, Clezy KR, Emery S, Kaplan E, McPhee DA, McLachlan AJ, Gelder FB, Lewin SR, Liauw W, Williams KM. A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals. HIV Clin Trials. 2004 Mar-Apr; 5(2): 91-98.
18. Verity EE, Williams LA, Haddad DN, Choy V, O'Loughlin C, Chatfield C, Saksena NK, Cunningham A, Gelder F, McPhee DA. Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody. AIDS. 2006 Feb 28;20(4):505-15. Erratum in: AIDS. 2006; 20(7): 1093-1094.
19. 12U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis. Antimicrobial Agents and Chemotherapy 2004; 48: 267-274.
20. SEPKOWITZ K A. AIDS - THE FIRST 20 YEARS. N Engl J Med 2001; 344: 1764-1772.
21. D'Olimpio JT, Elliston S, Dediego M, Sodum R. Orexigenic and cytoprotective effects of a novel adenosine-enriched peptide nucleic acid compound: Implications for clinical application. Journal of Clinical Oncology 2007; 25 (18S): 14154.
22. Lee-Huang S, Huang PL, Chen HC, Huang PL, Bourinbaiar A, Huang HI, Kung HF. Anti-HIV and antitumor activities of recombinant MAP30 from bitter melon. Gene. 1995;161(2):151-156.
23. Lee-Huang S, Huang PL, Huang PL, Bourinbaiar AS, Chen HC, Kung HF. Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31. Proc Natl Acad Sci. 1995; 92 (19): 8818-8822.
24. Khorram Khorshid HR, Abdollahi M, Novitsky YA, Shahhosseiny MH, Sadeghi B, Madani H, Rahimi R, Farzamfar B. Studies on potential Mutagenic and Genotoxic activity of Setarud. Daru 2008; 16 (4): 223-228.
25. Khorram Khorshid HR, Azonov JA, Novitsky Y, Shahhosseiny MH. Hepatoprotective effects of setarud against carbon tetrachloride-induced liver injury in rats. Ind J Gastro 2008; 27: 110-112.
26. Azonov JA, Khorram Khorshid HR, Novitsky YA, Farhadi M, Ghorbanoghli Z, Shahhosseiny MH. Protective effects of setarud (IMOD™) on development of diet-induced hypercholesterolemia in rabbits. Daru 2008; 16 (4): 218-222.
27. Khairandish P, Mohraz M, Farzamfar B, Abdollahi M , Shahhosseiny MH, Madani H, Sadeghi B, Heshmat R, Gharibdoust F, Khorram Khorshid HR. Preclinical and phase 1 clinical safety of Setarud (IMOD™), a novel candidate immune modulator drug. Daru 2009; 17(3): 148-156.
28. Hartmann M, Rump A, Brust J, Schuster D, Mosthaf F, Procaccianti M, Klinker H, Petzoldt D. Evaluation of an efavirenz-containing regimen: an open-label, multicenter study. HIV Clin Trials 2001; 2 (5): 421-428.
29. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004; 53 (5): 696-699.
30. Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother 2005; 55 (4): 413-416.